Skip to content

Kelly Holman

Managing Director, Genesys Capital

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 29 investments. He currently serves on the Board of Directors of Functional Neuromodulation Ltd. and from 2012-2015, he was a board observer with Invitae. From 2001 to 2013, he served on the board of Epocal, a Genesys portfolio company acquired by Alere (NYSE: ALR). Mr. Holman also sits on the Board of Directors of the Ontario Biotechnology Innovation Organization (OBIO)

Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer’s disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s University.